Induced pluripotent stem cell–derived human platelets: one step closer to the clinic by Gekas, Christos & Graf, Thomas
2781
Minireview
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 207 No. 13  2781-2784
www.jem.org/cgi/doi/10.1084/jem.20102428
A wide variety of cell types have been 
generated from mouse embryonic stem 
cells (ESCs) and human ESCs (hESCs), 
including  blood  cells,  neurons,  and   
heart  cells  (Olsen  et  al.,  2006;  Dhara   
et al., 2009; Lengerke and Daley, 2010; 
Yoshida and Yamanaka, 2010). This has 
opened up exciting prospects for the 
use of hESCs in regenerative medicine. 
However,  two  major  limiting  factors 
need to be addressed before pluripotent 
stem  cell–based  therapies  can  come 
to fruition. Although hESCs express 
low levels of major histocompatibil-
ity class (MHC) molecules, MHC ex-
pression increases with differentiation. 
Thus, differentiated progeny of hESCs 
may  express  MHC  levels  sufficient   
to cause rejection in genetically mis-
matched  patients  receiving  hESC- 
derived cells. This issue may be addressed 
by the discovery of induced pluripo-
tent stem (iPS) cells, which can be gen-
erated from somatic cells by de novo 
expression of four “reprogramming” 
transcription factors: Oct4, Klf4, Sox2, 
and c-Myc (Takahashi and Yamanaka, 
2006).  Because  it  appears  that  essen-
tially all somatic cell types tested thus 
far  can  be  reprogrammed  into  iPS 
cells  (Jaenisch,  2009;  Stadtfeld  and   
Hochedlinger, 2010), iPS cells can be 
generated  from  individual  patients, 
thereby avoiding the use of allogeneic 
cell sources for therapy.
However, because all ESCs and iPS 
cells  are  inherently  tumorigenic  and 
form  teratomas  in  vivo,  regardless   
of  the  reprogramming  method  (e.g., 
integration-free, small molecule, etc.), 
differentiated cell cultures intended for 
cell replacement therapy must be com-
pletely  free  of  contamination  with 
residual pluripotent cells. One of the 
ways in which pluripotent cells can be 
eliminated is by cell irradiation; how-
ever, this method is only suitable for 
red blood cells and platelets, which are 
enucleated and thus resistant to irra-
diation. For all other cell derivatives,   
alternative strategies have to be used, 
such  as  the  introduction  of  suicide 
genes that ablate remaining iPS cells or 
the pharmacological inhibition of anti-
apoptotic genes specifically expressed 
in pluripotent, but not differentiated, 
ESCs (Schuldiner et al., 2003; Blum 
et al., 2009).
It is noteworthy that despite inten-
sive efforts, in vitro differentiation of 
pluripotent stem cells into tissues of   
interest remains challenging, and that 
only a fraction of the several hundred 
specialized  cell  types  in  the  human 
body have been generated. The most 
successful model for ESC differentiation 
is the hematopoietic system. To date, 
most  mature  cell  types,  including 
erythrocytes, monocytes, natural killer 
cells, B and T lymphocytes, and plate-
lets  have  been  differentiated  from   
ESCs in vitro. Nevertheless, with the ex-
ception of erythrocytes, the process is 
either  too  inefficient  for  clinical  use 
and/or the differentiated cells do not 
exhibit  full  functionality  (Lengerke   
and  Daley,  2010).  In  this  issue  of   
the  Journal  of  Experimental  Medicine, 
Takayama et al. describe a novel iPS-
based approach to produce fully func-
tional  human  platelets  that  could  be 
useful in the clinic.
Generation of platelets in vitro
Platelet transfusions reduce the risk of 
severe bleeding in a wide range of pa-
tients  and  are  a  commonly  practiced 
clinical procedure (Wallace et al., 1995). 
However, platelet transfusions are costly 
and may lead to immune system com-
plications such as sepsis (Kruskall, 1997), 
underlining a real need for alternative 
platelet therapies. Platelets are the prog-
eny of megakaryocytes, a rare popula-
tion of hyperploid cells that reside in 
the adult bone marrow, and are gen-
erated by the extension of pro-plate-
let–like filopodia into the vasculature; 
these  extensions  shed  thousands  of 
cell fragments into the circulation un-
der  the  shear  force  of  blood  flow 
(Schulze and Shivdasani, 2005; Junt 
et al., 2007). The formation of mega-
karyocytes and platelets requires specific 
transcription factors, including GATA-1, 
NF-E2, and SCL, which also play key 
roles in erythropoiesis (Shivdasani and 
Orkin, 1995; Mikkola et al., 2003). 
The era of induced pluripotent stem (iPS) cells carries with it the promise of 
virtually unlimited sources of autologous cells for regenerative medicine. 
However, efficiently differentiating iPS cells into fully functional mature 
cell types remains challenging. A new study reporting the formation of fully 
functional platelets from human iPS (hiPS) cells improves upon recent 
efforts to generate this enucleated cell type, which remains in high demand 
for therapeutic transfusions. Notably, their lack of nucleus renders platelets 
unable to retain the pluripotent or tumorigenic properties of iPS cells.
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megakaryocyte  under  these  conditions 
was improved by approximately two- to 
threefold compared with their previous 
study (Takayama et al., 2008). The hiPS-
derived platelets were detectable in the 
circulation for at least 24 h after transfu-
sion into irradiated NOD-SCID-Il2rg
/ 
mice. Importantly, intravital microscopy 
revealed that upon laser-induced vessel 
injury,  the  transfused  platelets  partici-
pated in the formation of blood clots, 
showing for the first time the formation 
of functional platelets from pluripotent 
human cells in an in vivo assay.
Role of c-MYC in iPS  
and platelet generation
Takayama et al. (2010) also provide in-
sight into the role of c-MYC in the for-
mation of megakaryocytes and platelets. 
Previous work using transgenic mice 
overexpressing c-Myc under the con-
trol of the platelet-specific promoter 
PF4 showed a small but significant in-
crease in the number of low ploidy 
megakaryocytes  and  a  reduction  in 
and CD61 (integrin 3 or GPIIIa) and 
could be activated in response to ADP 
and thrombin. However, hESC-derived 
megakaryocytes contained fewer gran-
ules and yielded far fewer platelets than 
their  normal  counterparts  (2–3  com-
pared  with  1,000-3,000  per  mega-
karyocyte; Stenberg and Levin, 1989; 
Takayama et al., 2008). In addition, the   
in vivo functionality of the ES sac– 
derived platelets was not demonstrated.
Takayama et al. (2010) now report 
the  generation  of  hiPS  cell–derived 
megakaryocytes  and  platelets  with  in 
vivo functionality. The main difference 
between  this  study  and  their  previous 
work  is  the  use  of  hiPS  cells  derived 
from human dermal fibroblasts instead 
of hESCs. In brief, hiPS cells were co-
cultured on C3H10T1/2 feeder cells in 
the presence of VEGF for 14–15 d, and 
the resulting hiPS sacs were replated in 
the presence of human TPO and other 
cytokines (IL-6, IL-11, and SCF) for an 
additional 8–12 d to form megakaryo-
cytes  (Fig.  1).  The  platelet  yield  per 
In addition, megakaryocyte numbers, 
maturation,  and  pro-platelet  forma-
tion  are  dependent  on  thrombopoi-
etin (TPO; Kaushansky, 2005; Gaur   
et al., 2006)
Using mouse ESCs, several groups 
managed  to  produce  platelets  and/or 
megakaryocytes  in  vitro  (Eto  et  al., 
2003; Fujimoto et al., 2003; Kennedy 
and  Keller,  2003).  The  generation  of 
mature megakaryocytes from hESCs was 
first reported by Gaur et al. (2006). The 
hESCs were differentiated on OP9, a 
bone marrow stromal cell line derived 
from mice lacking macrophage colony-
stimulating factor (Nakano et al., 1994), 
which has been widely used to support 
differentiation of both mouse ESCs and 
hESCs into hematopoietic cells in vitro.   
The ESC-derived megakaryocytes ob-
tained  after  15–17  d  of  co-culture 
supplemented  with  TPO  expressed 
specific surface antigens, including the   
lineage markers CD41a (integrin IIb or 
GPIIb) and CD42b (GPIb). However, 
platelets were not detected (Gaur et al., 
2006). More recently, Takayama et al. 
(2008) improved upon the protocol of 
Gaur et al. (2006) by co-culturing ESCs 
on either OP9 or C3H10T1/2 stroma 
for an initial period of 14–15 d with vas-
cular endothelial growth factor (VEGF). 
This led to the formation of so-called 
ES-sacs,  which  are  sac-like  structures 
consisting of a morphologically distinct 
outer layer of cells with endothelial-like 
properties. ESC sacs also contain a robust 
population of round hematopoietic-like 
cells expressing shared markers of blood 
and endothelium, such as VE-cadherin 
and CD31, as well as the hematopoietic 
cell-specific markers CD34, CD41a, 
and  CD45  (Takayama  et  al.,  2008). 
These hematopoietic cells have the ca-
pacity to form hematopoietic colonies 
in vitro, suggesting that ESC sacs serve 
as an endothelial-type niche for early 
blood cell progenitors. When cultured 
for 24 d in medium that was first sup-
plemented with VEGF and then with 
TPO plus other cytokines (interleukin   
[IL]-6, IL-11, and stem cell factor [SCF]), 
the hematopoietic progenitors from ESC 
sacs formed megakaryocytes. In addition, 
megakaryocytes obtained in this manner 
released platelets that expressed CD41a 
Figure 1.  The generation of human platelets from hiPS cells and the role of c-MYC. iPS 
cells are generated by the reprogramming of human dermal fibroblasts (HDFs) with the transcription 
factors OCT4, KLF4, SOX2, and c-MYC (OKSM). In hiPS cells, exogenous c-MYC levels are initially  
high and activate expression of endogenous c-MYC. Exogenous c-MYC expression subsequently de-
creases. Co-culture with stromal cells in the presence of VEGF drives formation of an iPS sac con-
taining hematopoietic progenitors. Further culture in megakaryocyte (Mk) conditions (TPO, SCF, and 
heparin) reactivates exogenous c-MYC expression, leading to the differentiation of megakaryocytes. 
Down-regulation of exogenous c-MYC expression leads to the efficient production of platelets, 
whereas sustained exogenous c-MYC expression inhibits platelet generation. Platelets obtained with 
this protocol, when transferred into mice, can participate in thrombus formation after vessel injury.JEM VOL. 207, December 20, 2010 2783
Minireview
Chanprasert, S., A.E. Geddis, C. Barroga, N.E. Fox, 
and K. Kaushansky. 2006. Thrombopoietin 
(TPO) induces c-myc expression through a 
PI3K- and MAPK-dependent pathway that 
is not mediated by Akt, PKCzeta or mTOR 
in  TPO-dependent  cell  lines  and  primary 
megakaryocytes. Cell. Signal. 18:1212–1218. 
doi:10.1016/j.cellsig.2005.09.010
Dhara,  S.K.,  B.A.  Gerwe,  A.  Majumder,  M.C. 
Dodla,  N.L.  Boyd,  D.W.  Machacek,  K. 
Hasneen, and S.L. Stice. 2009. Genetic ma-
nipulation of neural progenitors derived from   
human embryonic stem cells. Tissue Eng. Part A. 
15:3621–3634. doi:10.1089/ten.tea.2009.0155
Eto,  K.,  A.L.  Leavitt,  T.  Nakano,  and  S.J. 
Shattil. 2003. Development and analysis of 
megakaryocytes  from  murine  embryonic 
stem  cells.  Methods  Enzymol.  365:142–158. 
doi:10.1016/S0076-6879(03)65010-X
Fujimoto,  T.T.,  S.  Kohata,  H.  Suzuki,  H. 
Miyazaki, and K. Fujimura. 2003. Production 
of functional platelets by differentiated embry-
onic stem (ES) cells in vitro. Blood. 102:4044–
4051. doi:10.1182/blood-2003-06-1773
Gaur,  M.,  T.  Kamata,  S.  Wang,  B.  Moran, 
S.J. Shattil, and A.D. Leavitt. 2006. Mega-
karyocytes derived from human embryonic 
stem cells: a genetically tractable system to study 
megakaryocytopoiesis and integrin function. 
J. Thromb. Haemost. 4:436–442. doi:10.1111/
j.1538-7836.2006.01744.x
Guo, Y., C. Niu, P. Breslin, M. Tang, S. Zhang, 
W. Wei, A.R. Kini, G.P. Paner, S. Alkan, 
S.W. Morris, et al. 2009. c-Myc-mediated   
control  of  cell  fate  in  megakaryocyte- 
erythrocyte  progenitors.  Blood.  114:2097–
2106. doi:10.1182/blood-2009-01-197947
Jaenisch, R. 2009. Stem cells, pluripotency and nu-
clear reprogramming. J. Thromb. Haemost. 7:21–
23. doi:10.1111/j.1538-7836.2009.03418.x
Junt, T., H. Schulze, Z. Chen, S. Massberg, T. 
Goerge,  A.  Krueger,  D.D.  Wagner,  T. 
Graf, J.E. Italiano Jr., R.A. Shivdasani, and 
U.H.  von  Andrian.  2007.  Dynamic  visu-
alization  of  thrombopoiesis  within  bone 
marrow.  Science.  317:1767–1770.  doi:10 
.1126/science.1146304
Kaushansky, K. 2005. The molecular mechanisms 
that control thrombopoiesis. J. Clin. Invest. 
115:3339–3347. doi:10.1172/JCI26674
Kennedy,  M.,  and  G.M.  Keller.  2003.  Hema-
topoietic  commitment  of  ES  cells  in  cul-
ture.  Methods  Enzymol.  365:39–59.  doi:10 
.1016/S0076-6879(03)65003-2
Kerenyi,  M.A.,  and  S.H.  Orkin.  2010.  Net-
working  erythropoiesis.  J.  Exp.  Med.  207: 
2543–2550.
Kruskall, M.S. 1997. The perils of platelet trans-
fusions.  N.  Engl.  J.  Med.  337:1914–1915. 
doi:10.1056/NEJM199712253372609
Lengerke, C., and G.Q. Daley. 2010. Autologous 
blood  cell  therapies  from  pluripotent  stem 
cells.  Blood  Rev.  24:27–37.  doi:10.1016/ 
j.blre.2009.10.001
Mikkola, H.K., J. Klintman, H. Yang, H. Hock, 
T.M. Schlaeger, Y. Fujiwara, and S.H. Orkin. 
2003. Haematopoietic stem cells retain long- 
term  repopulating  activity  and  multipotency   
day 22, but not when c-MYC expres-
sion  was  extended  to  day  26.  It  is   
also  noteworthy  that  overexpression  of   
c-MYC in ESCs to levels that are inhibi-
tory for platelet formation activate the   
expression of the senescence-inducing 
p14  (ARF)  and  p16  (INK4A)  genes. 
p14 (ARF) and p16 (INK4A) expres-
sion was not activated in the iPS clone 
that transiently expressed c-MYC and 
showed the highest platelet production 
efficiency. This indicates that a narrow 
window of c-MYC expression is re-
quired for efficient platelet development. 
Which, if any, of the observed effects of 
sustained c-MYC expression is the cause 
of the observed inhibition of platelet 
formation remains to be determined.
Thus, optimal platelet formation from 
patient-derived somatic cells requires 
two waves of c-MYC expression; the 
first contributes to the efficient repro-
gramming of somatic cells into hiPS cells 
(together with the other reprogram-
ming factors) and the second mediates 
ES/iPS sac and megakaryocyte forma-
tion (Fig. 1). However, c-MYC expres-
sion has to be shut off to permit efficient 
platelet formation. In line with this in-
terpretation is the finding that distinct 
threshold  levels  of  c-Myc  govern  its 
output in vivo. Although low levels of 
deregulated c-Myc are sufficient to in-
duce oncogenesis and ectopic prolifera-
tion of somatic cells, activation of the 
apoptotic and ARF/p53 intrinsic tumor 
surveillance pathways requires high c-Myc   
expression (Murphy et al., 2008).
No matter what roles c-Myc plays in 
the  formation  of  megakaryocyte  and 
platelets, the new work represents a step 
closer to the use of a highly desired cell 
type derived from iPS cells for cell re-
placement therapies. This prospect is all 
the more exciting because platelets are 
enucleated cells that can be irradiated, 
thereby eliminating safety concerns caused 
by the presence of contaminating iPS cells 
with the potential to cause tumors.
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